The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration

被引:28
作者
Davis, JL
Papich, MG
Weingarten, A
机构
[1] N Carolina State Univ, Coll Vet Med, Clin Pharmacol Lab, Dept Mol & Biomed Sci, Raleigh, NC 27606 USA
[2] Schering Plough Corp, Anim Hlth, Union, NJ USA
关键词
D O I
10.1111/j.1365-2885.2006.00737.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to determine the pharmacokinetics and physicochemical characteristics of orbifloxacin in the horse. Six healthy adult horses were administered oral and intravenous orbifloxacin at a dose of 2.5 mg/kg. Plasma samples were collected and analyzed by high-pressure liquid chromatography with ultraviolet detection. Plasma protein binding and lipophilicity were determined in vitro. Following i.v. administration, orbifloxacin had a terminal half-life (t(1/2)) of 5.08 h and a volume of distribution (V-d(ss)) of 1.58 L/kg. Following oral administration, the average maximum plasma concentration (C-max) was 1.25 mu g/mL with a t(1/2) of 3.42 h. Systemic bioavailability was 68.35%. Plasma protein binding was 20.64%. The octanol:water partition coefficient (pH 7.4) was 0.2 +/- 0.11. No adverse reactions were noted during this study. Dosage regimens were determined from the pharmacokinetic-pharmacodynamic parameters established for fluoroquinolone antibiotics. For susceptible bacteria, an oral dose of approximately 5 mg/kg once daily will produce plasma concentrations within the suggested range. This dose is suggested for further studies on the clinical efficacy of orbifloxacin for treatment of susceptible bacterial infections in the horse.
引用
收藏
页码:191 / 197
页数:7
相关论文
共 33 条
[1]   The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs:: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae [J].
Ambrose, PG ;
Grasela, DM .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (03) :151-157
[2]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[3]  
ASHBY J, 1985, J ANTIMICROB CHEMOTH, V16, P805
[4]   ACCUMULATION AND KILLING KINETICS OF 15 QUINOLONES FOR ESCHERICHIA-COLI, STAPHYLOCOCCUS-AUREUS AND PSEUDOMONAS-AERUGINOSA [J].
ASUQUO, AE ;
PIDDOCK, LJV .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (06) :865-880
[5]  
BERMINGHAM E, 1998, J VET INTERNAL MED, V12, P218
[6]   Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs [J].
Bidgood, TL ;
Papich, MG .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2005, 28 (04) :329-341
[7]   Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs [J].
Bidgood, TL ;
Papich, MG .
AMERICAN JOURNAL OF VETERINARY RESEARCH, 2003, 64 (08) :1040-1046
[8]   Pharmacokinetics of marbofloxacin in horses [J].
Bousquet-Melou, A ;
Bernard, S ;
Schneider, M ;
Toutain, PL .
EQUINE VETERINARY JOURNAL, 2002, 34 (04) :366-372
[9]   Pharmacokinetics of marbofloxacin in mature horses after single intravenous and intramuscular administration [J].
Carretero, M ;
Rodríguez, C ;
San Andrés, MI ;
Forés, P ;
De Lucas, JJ ;
Nieto, J ;
Waxman, S ;
San Andrés, MD ;
González, F .
EQUINE VETERINARY JOURNAL, 2002, 34 (04) :360-365
[10]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10